Navigation Links
Protein Sciences Prepared to Combat the Latest Potential Pandemic Flu Virus

MERIDEN, Conn., May 2, 2013 /PRNewswire/ -- Protein Sciences announced today that it had completed development of the vector required to manufacture a vaccine to protect against the new and deadly H7N9 Bird Flu and is prepared to commence manufacturing within a few days of receiving orders for the vaccine.

It has been possible to move quickly and safely to develop the H7N9 vaccine because we use modern, proprietary, recombinant technology that enables us to develop vaccines for potentially deadly viruses without the use of a live disease virus and, therefore, without any risk to personnel.

We could manufacture the vaccine in our Pearl River, NY facility that we leased from Pfizer in November 2012.  In just 100 days we have been able to renovate the facility, restore it to full operating condition for our technology and manufacture three lots of antigens for our seasonal influenza vaccine, Flublok® that was approved by the FDA in January 2013.  Significant help in the process has been obtained from the State of New York and Rockland County and from current and former Pfizer personnel who have been incredibly helpful and supportive.

Manon Cox , President and CEO of Protein Sciences said, "We are excited that we have been able to move so quickly on the H7N9 vaccine.  We have consistently been first to have vaccines for potential pandemics, including manufacturing the first pandemic vaccine in 1997-98 in response to the Hong Kong Bird Flu.  We are very grateful for support from the Centers for Disease Control and Prevention who provided us with a killed H7N9 virus that allowed us to start the process."  She added, "Our Pearl River manufacturing facility has sufficient capacity to allow us to manufacture more than twice the number of doses of pandemic influenza vaccine in a six month period than is required by our contract with the Biomedical Advanced Research and Development Authority (BARDA)."

About Us

Protein Sciences Corporation is a vaccine development and protein production company that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceu­ticals.  

On January 16, 2013, the U.S. FDA approved Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease, for use in adults 18-49 years old. 

Flublok and its sister vaccine, Panblok®, that is designed to protect against pandemic influenza, have been developed in partnership with BARDA through Contract No. HHS0100200900106C. 

Learn more at and

SOURCE Protein Sciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
2. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
3. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
4. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
5. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
6. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
7. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
8. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
9. Ventana Medical Systems, Inc. develops first-ever fully automated dual-stain technique for miRNA and protein detection in cancer
10. ProteinSimple Charges Ahead with the Simple Western
11. Advantages of Pressure BioSciences PCT Platform Highlighted at a Recent International Scientific Conference Focused on the Role of Proteins in the Cause, Prevention, and Treatment of Disease
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... N.Y. , Nov. 25, 2015  Linden Care, ... and optimizing treatment outcomes for patients suffering from chronic ... request for a Temporary Restraining Order (TRO) enjoining Express ... the two companies. --> ... pursuing all of its legal options. ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again with ... the possibilities are endless. Users have full control over angle of view, speed method, ... users are sure to get heads to turn. , ProPanel: Pulse offers fully customizable ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... out by the University of Toronto and the University of British Columbia suggested that ... for head injuries. The article explains that part of the reason for the controversial ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has ... it. Surviving Mesothelioma has just posted the findings on the website. Click here ... the cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP ...
(Date:11/27/2015)... ... 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that will ... their purchase of lice treatment product. In addition, customers will receive a complimentary head ... “Finding lice is a sure way to ruin the holidays, so we encourage all ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that ... ). More than 3.7 billion people under the age of 50 – or 67% ... WHO's first global estimates of HSV-1 infection . , "The data shocks us highly!" ...
Breaking Medicine News(10 mins):